.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Diving into Data Trends and Ongoing Research in Advanced Endometrial Cancer

Christian Marth, MD, PhD, and John Chan, MD, discuss the latest data trends in advanced endometrial cancer.

EP. 1: Current Treatment Strategies and Challenges in Frontline Advanced Endometrial Cancer

March 26th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss frontline treatment trends and challenges in advanced endometrial cancer.

EP. 2: LEAP-001 Data for First-Line Lenvatinib/Pembrolizumab in Advanced Endometrial Cancer

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss data for frontline lenvatinib plus pembrolizumab in advanced endometrial cancer.

EP. 3: Subgroup Data for Lenvatinib/Pembrolizumab In Frontline Advanced Endometrial Cancer After Perioperative Chemo

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss subgroup data for frontline lenvatinib/pembrolizumab in endometrial cancer after perioperative chemotherapy.

EP. 4: The Role of IO/Chemo Combinations in Frontline Advanced/Recurrent Endometrial Cancer

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss frontline chemoimmunotherapy combinations in advanced endometrial cancer.

EP. 5: ADCs and Novel Agents Under Investigation in Advanced Endometrial Cancer

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss antibody-drug conjugates and agents under evaluation in endometrial cancer.

EP. 6: Ongoing Research to Watch in Advanced Endometrial Cancer in 2025

March 28th 2025

Christian Marth, MD, PhD, and John Chan, MD, discuss ongoing research to watch in endometrial cancer.